Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 10:56 am Sale | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | Foresite Capital Fund IV, L.P. | 1,412,705 6.100% | -15,366 (-1.08%) | Filing History |
| 2021-02-16 10:46 am Sale | 2020-12-31 | 13G | Arbutus Biopharma Corporation ABUS | Foresite Capital Fund IV, L.P. | 0 0.000% | -3,705,128 (Position Closed) | Filing History |
| 2021-02-12 3:26 pm Purchase | 2021-02-05 | 13G | Pharvaris N.V. PHVS | Foresite Capital Fund IV, L.P. | 3,926,068 12.300% | 3,926,068 (New Position) | Filing History |
| 2020-12-14 9:24 pm Purchase | 2020-12-03 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund IV, L.P. | 10,838,311 25.000% | 10,838,311 (New Position) | Filing History |
| 2020-08-03 3:28 pm Purchase | 2020-07-24 | 13G | Nurix Therapeutics, Inc. NRIX | Foresite Capital Fund IV, L.P. | 3,160,784 8.500% | 3,160,784 (New Position) | Filing History |